Sutro Biopharma Inc STRO

NAS: STRO | ISIN: US8693671021 30/04/2025

1,050 USD (+20,04%)

(+20,04%) 30/04/2025

Grafiek Sutro Biopharma Inc

Grafiek Sutro Biopharma Inc

1 dag1d 20,04%
1 week1w -19,23%
1 maand1m 76,38%
3 maanden3m -44,74%
6 maanden6m -70,42%
1 jaar1j -71,93%
5 jaar5j -88,92%

Sutro Biopharma Inc in het nieuws

Toon enkel gratis nieuws

28 juni 2022 · Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs) · Persbericht

29 april 2022 · Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

8 april 2022 · Sutro Biopharma Presents Nonclinical Data for Antibody-Drug Conjugate STRO-002 at the AACR Annual Meeting 2022 · Persbericht

5 april 2022 · Sutro Biopharma to Present at the 21st Annual Needham Virtual Healthcare Conference · Persbericht

30 maart 2022 · Sutro Biopharma Presented on Advances in Novel Immunostimulatory Antibody-Drug Conjugate Modality at the 12th Annual World ADC · Persbericht

3 maart 2022 · Sutro Biopharma to Participate in the Cowen 42nd Annual Healthcare Conference · Persbericht

28 februari 2022 · Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones · Persbericht

6 januari 2022 · Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference · Persbericht

5 januari 2022 · Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer · Persbericht

13 december 2021 · Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021 · Persbericht

Profiel Sutro Biopharma Inc

Gezondheidstechnologie

Website: www.sutrobio.com

Hoofdzetel: South San Francisco, California Verenigde Staten

CEO: William Newell

Werknemers: 260

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe